Elaine Beitler most recently served as Chief Executive Officer and member of the Board of Directors of BROWZ, LLC, a former MCM portfolio company.
Previously, Ms. Beitler spent thirteen years with Bowne & Co., Inc., a shareholder and marketing communication services company, where she held various executive leadership roles including Corporate Officer, President of Marketing and Business Communications, Chief Information Officer, and Senior Vice President of the digital and offset manufacturing operations.
Prior to joining Bowne, she worked at Seagram & Sons, Co. Ltd. where she led technology based world-wide initiatives and integrations of newly acquired businesses.
Richard H. Brown
Richard H. Brown is the former Chairman of the Board of Browz LLC, a former MCM portfolio company.
Mr. Brown was Chairman and Chief Executive Officer of Electronic Data Systems Corporation, Chief Executive Officer of Cable & Wireless plc, H&R Block Inc. and Illinois Bell Telephone Company. Mr. Brown also served as Chairman of the Board of Chemours from 2015-2021; a director of E. I. du Pont de Nemours and Company from 2001-2015 and as a director of Home Depot.
He is a trustee emeritus of the Ohio University Foundation and formerly served as a member of the Business Roundtable, the President’s Advisory Committee on Trade and Policy Negotiations, the U.S.-Japan Business Council, the French-American Business Council, and the President’s National Security Telecommunications Advisory Committee.
Virinder Nohria, MD PhD
Dr. Virinder Nohria is an experienced physician, biotechnology entrepreneur and a drug developer. Dr. Nohria has worked with MCM since 2006, when the Firm became affiliated with Alaven Pharmaceutical, a former MCM investment, where he was a member of the founding team and Chief Medical Officer, Chief Compliance Officer and Executive Vice President.
Previously, Dr. Nohria has worked for Eli Lilly and UCB, where he was critical in the launch of two blockbuster products. Dr. Nohria was Vice President and Chief Medical Officer of Xcel Pharmaceuticals, a specialty pharmaceutical company in neuroscience that was acquired by Valeant International in 2005. At Xcel Dr. Nohria was responsible for acquiring worldwide rights to a phase III product in neuroscience, which he helped develop into a drug that has now been partnered with a major global pharmaceutical company and launched in most major markets worldwide.
Dr. Nohria is a board-certified neurologist with special qualifications in child neurology. He completed his medical training at the University of Cambridge in England. His postgraduate training was completed in the UK and US at Duke University. He also holds a Ph.D. degree in Neuropharmacology. Dr. Nohria was a Co-Founder and President of Vidara Therapeutics LLC, a prior MCM portfolio company. He is an active board member of Sebela Pharmaceuticals, a current MCM portfolio company.